EGFR and non-small cell lung carcinoma: Its mechanism of action is to inhibit the autophosphorylation of intracellular zone receptor tyrosine kinase or competitively suppress the binding of receptor tyrosine kinase ATP to the EGFR site, blocking downstream signaling and is primarily used in the clinical management of advanced non‐small cell lung cancer (NSCLC).